Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
World Courier is the most trusted specialty logistics company in the world for clinical trials. The general manager of the Mexico affiliate discusses the challenges clients face in the country…
The president of the Mexican Society of Cardiology sat down with us to share his view of the cardiology medical field in the country, why Mexico needs to collaborate more…
Novartis strives for “creating solutions for patients that go beyond the pill”. The country head and next president of CANIFARMA discusses how the company is using new programs and technology…
Considered one of the leading medical authorities in the country, David Kershenobich provides an overview about the new challenges faced by the Mexican healthcare system with the transition from infectious…
Thanks to the recognition COFEPRIS received from the Pan-American Health Organization as national regulatory authority of regional reference, Mexican manufacturers are increasingly eyeing foreign markets to grow. The general manager…
Healthcare is one of the next items on President Peña Nieto’s busy agenda. The objective: moving Mexico towards universal healthcare coverage. The initiative was started at the beginning of 2000…
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Dr. José Angel Cordova Villalobos shares his experience as former Minister of Health and illustrates how the unification of today’s fragmented healthcare system is the only way to provide effective…
The opening of the Mexican Social Security Institute (IMSS) to clinical research is a unique opportunity for Mexico to step up on the international scenario for clinical trials. The CEO of…
Store brands are Perrigo’s core business. The vice president and managing director of the Mexican and Latin American affiliate discusses the company’s pioneer and early vision to bet on generics…
The executive director of the university spin-off UDIMEB explains the major achievements of the institution, her plans to convert it into a strategic partner to the pharmaceutical and biotechnology industry to…
The partner and leader of the healthcare practice for Mexico and Hispanic America shares his vision about how Mexico’s healthcare sector is converging to look at innovative ways to understand…
See our Cookie Privacy Policy Here
